Industry Overview - Collagen masks are mainstream skincare products focused on anti-aging and repair, utilizing collagen as the core ingredient along with auxiliary components to achieve hydration and skin barrier repair [1][2] - The Chinese mask industry is expected to reach a market size of 72.986 billion yuan in 2024, entering a period of adjustment and transformation, facing growth slowdown and intensified competition [1][6] - The collagen market is experiencing explosive growth, with a compound annual growth rate (CAGR) of 41.9% from 2020 to 2023, and retail scale expected to exceed 269.5 billion yuan by 2030 [1][7] Market Dynamics - The market structure in China shows that sheet masks remain dominant, while cream masks are rapidly growing, focusing on hydration and repair needs [1][7] - The competitive landscape features local leaders dominating, niche players breaking through, and international brands penetrating the market, with a clear price gradient and significant differentiation between high, medium, and low-end markets [1][8] Industry Chain - The upstream of the collagen mask industry primarily uses animal-derived collagen, while recombinant collagen is rapidly developing due to its high purity and compatibility with mask formulations [6][10] - The manufacturing process involves various technologies to convert raw materials into different forms and functions of mask products, with sales channels dominated by online e-commerce and deepening offline professional channels [6][10] Current Development - The Chinese mask industry is transitioning into a phase of deep integration after rapid growth, with three emerging drivers leading market changes: consumption upgrades, male skincare market expansion, and personalized demand fostering innovative scenarios [6][7] - The market size is projected to steadily grow to 76.79 billion yuan by 2025 and potentially exceed 146.42 billion yuan by 2030, indicating robust long-term growth prospects [6][7] Key Players - Major companies in the collagen mask industry include Juzi Biotechnology, Huaxi Biotechnology, and Marubi Biotechnology, leveraging differentiated technologies and channel advantages to lead the market [2][10] - The industry is characterized by a multi-faceted competitive ecosystem, with local leaders, niche players, and international brands all contributing to the market dynamics [10] Future Trends - The industry is expected to advance towards high-end technology, refined products, and standardized ecosystems, with a focus on cross-disciplinary technology integration and precise formulations [10][12] - Regulatory tightening is anticipated to accelerate the elimination of smaller brands, increasing market concentration, while leading companies will strengthen their market positions through R&D innovation and global expansion [10][14]

Market Overview - On December 1, the cosmetics sector rose by 0.26% compared to the previous trading day, with BAWI leading the gains [1] - The Shanghai Composite Index closed at 3914.01, up 0.65%, while the Shenzhen Component Index closed at 13146.72, up 1.25% [1] Individual Stock Performance - BAWI shares closed at 15.93, up 2.38% with a trading volume of 16,900 lots and a transaction value of 26.70 million yuan [1] - Shanghai Jahwa closed at 23.61, up 1.77% with a trading volume of 49,400 lots and a transaction value of 116 million yuan [1] - Huachun Color closed at 28.22, up 1.00% with a trading volume of 16,000 lots and a transaction value of 45.40 million yuan [1] - Betaini closed at 41.52, up 0.56% with a trading volume of 27,900 lots and a transaction value of 116 million yuan [1] - Kohn shares closed at 16.44, up 0.55% with a trading volume of 161,900 lots and a transaction value of 263 million yuan [1] - Proya closed at 70.61, up 0.37% with a trading volume of 23,200 lots and a transaction value of 163 million yuan [1] - Qingdao King closed at 7.38, up 0.27% with a trading volume of 85,100 lots and a transaction value of 6.28 million yuan [1] - Marubi closed at 35.47, up 0.11% with a trading volume of 29,300 lots and a transaction value of 103 million yuan [1] - Lafang closed at 20.95, unchanged with a trading volume of 23,000 lots and a transaction value of 4.81 million yuan [1] - Qingsong shares closed at 7.53, down 0.13% with a trading volume of 129,100 lots and a transaction value of 96.89 million yuan [1] Fund Flow Analysis - The cosmetics sector experienced a net outflow of 49.52 million yuan from institutional funds, while retail investors saw a net inflow of 51.08 million yuan [2] - The overall fund flow indicates a mixed sentiment, with institutional investors pulling back while retail investors are increasing their positions [2] Detailed Fund Flow by Stock - Jiahen Home's main funds saw a net inflow of 7.25 million yuan, while retail funds had a net outflow of 19.70 million yuan [3] - Shanghai Jahwa experienced a net inflow of 3.64 million yuan from main funds, with retail investors contributing a net inflow of 348.90 million yuan [3] - Kohn shares had a net inflow of 3.35 million yuan from main funds, but retail investors saw a net outflow [3] - BAWI experienced a net outflow of 0.50 million yuan from main funds, while retail investors had a net inflow of 164.42 million yuan [3] - Qingdao King saw a net outflow of 0.83 million yuan from main funds, but retail investors contributed a net inflow of 238.25 million yuan [3]

Group 1 - The cosmetics sector increased by 0.29% on November 28, with Jiaheng Jiahua leading the gains [1] - The Shanghai Composite Index closed at 3888.6, up 0.34%, while the Shenzhen Component Index closed at 12984.08, up 0.85% [1] - Jiaheng Jiahua's stock price rose by 6.45% to 40.28, with a trading volume of 67,100 shares and a transaction value of 266 million yuan [1] Group 2 - The cosmetics sector experienced a net outflow of 61.04 million yuan from institutional investors, while retail investors saw a net inflow of 76.64 million yuan [2] - Among individual stocks, Marubi Biological had a net outflow of 9.46 million yuan from institutional investors, while Shanghai Jahwa saw a net inflow of 5.63 million yuan [3] - The overall trading activity in the cosmetics sector indicates a mixed sentiment, with some stocks experiencing significant outflows while others attracted retail interest [2][3]

中信证券股份有限公司 关于哈尔滨敷尔佳科技股份有限公司 2025年度持续督导培训情况报告 深圳证券交易所： 中信证券股份有限公司（以下简称"中信证券"、"保荐人"）作为哈尔滨敷尔 佳科技股份有限公司（以下简称"敷尔佳"或"公司"）首次公开发行股票并在创业 板上市的保荐人，根据《深圳证券交易所上市公司自律监管指引第 13 号——保 荐业务》的相关规定，对敷尔佳进行了 2025 年度持续督导培训，报告如下： 一、本次持续督导培训的基本情况 （一）保荐人：中信证券股份有限公司 （七）培训对象：公司控股股东及实际控制人、董事、高级管理人员、部分 中层以上管理人员及证券事务代表等相关人员 三、本次持续督导培训的结论 保荐人按照《深圳证券交易所上市公司自律监管指引第 13 号——保荐业务》 的有关要求，对敷尔佳进行了 2025 年度持续督导培训。 1 （二）保荐代表人：鄢凯红、范新亮 （三）协办人：陈溪峪 （四）培训时间：2025 年 11 月 19 日 （五）培训地点：公司会议室 （六）培训人员：鄢凯红 （八）培训内容：本次培训主要介绍 2025 年以来新修订法规主要修订内容， 并重点介绍《上市公司治理准则》修订内容及 ...

Core Viewpoint - The cosmetics sector experienced a 1.6% increase on November 27, with Keshare leading the gains, while the overall market showed mixed results with the Shanghai Composite Index rising by 0.29% and the Shenzhen Component Index declining by 0.25% [1] Group 1: Market Performance - The Shanghai Composite Index closed at 3875.26, up 0.29% [1] - The Shenzhen Component Index closed at 12875.19, down 0.25% [1] - The cosmetics sector's individual stock performance is detailed in a table, highlighting significant gainers such as Keshare with a 9.12% increase [1] Group 2: Individual Stock Performance - Keshare (300856) closed at 16.15 with a 9.12% increase and a trading volume of 310,700 shares, amounting to a transaction value of 489 million yuan [1] - Marubi Biological (603983) closed at 35.19, up 4.89%, with a trading volume of 87,200 shares and a transaction value of 304 million yuan [1] - Other notable performers include Water Sheep (300740) with a 2.72% increase and a transaction value of 580 million yuan [1] Group 3: Capital Flow Analysis - The cosmetics sector saw a net outflow of 25.34 million yuan from institutional investors and 82.57 million yuan from retail investors, while individual investors contributed a net inflow of 108 million yuan [2] - A detailed table shows the capital flow for individual stocks, indicating that LaFang (603630) had a net inflow of 5.96 million yuan from institutional investors [3] - Other stocks like Shanghai Jahwa (600315) and Huaye Fragrance (300886) also experienced varying degrees of net inflow and outflow from different investor categories [3]

Market Overview - The cosmetics sector experienced a decline of 1.1% on November 26, with Kesheng Co. leading the drop [1] - The Shanghai Composite Index closed at 3864.18, down 0.15%, while the Shenzhen Component Index closed at 12907.83, up 1.02% [1] Individual Stock Performance - Notable gainers included: - Shuiyang Co. (300740) with a closing price of 19.85, up 2.58% [1] - Fulejia (301371) also rose by 2.58% to 27.88 [1] - Major decliners included: - Kesheng Co. (300856) fell by 4.88% to 14.80 [2] - Marubi Bio (603983) decreased by 2.95% to 33.55 [2] - Jiahen Home (300955) dropped by 2.85% to 37.84 [2] Trading Volume and Capital Flow - The cosmetics sector saw a net inflow of 7.95 million yuan from institutional investors, while retail investors contributed a net inflow of 7.35 million yuan [2] - However, there was a net outflow of 15.30 million yuan from speculative funds [2] Detailed Capital Flow Analysis - Key stocks with significant capital flow: - Jiahen Home (300955) had a net inflow of 18.65 million yuan from institutional investors, but a net outflow of 19.54 million yuan from retail investors [3] - Fulejia (301371) saw a net inflow of 12.12 million yuan from speculative funds, despite a net outflow from retail investors [3] - Other stocks like Qingdao King (002094) and Shanghai Jahwa (600315) also experienced mixed capital flows, indicating varied investor sentiment [3]

Core Points - The stock price of Shiyijia (敷尔佳) has decreased by 2.48%, closing at 27.18 yuan [1] - Shiyijia was listed on the Shenzhen Stock Exchange's ChiNext board on August 1, 2023, with an initial share price of 55.68 yuan and a total issuance of 40.08 million shares [1][2] - The stock reached a peak price of 80.04 yuan on its first trading day but is currently in a state of decline [2] Fundraising and Financials - Shiyijia raised a total of 223.17 million yuan through its initial public offering (IPO), with a net amount of 207.18 million yuan, exceeding the original plan by 17.52 million yuan [2] - The company planned to raise 189.66 million yuan for projects including production base construction, R&D and quality testing center, brand marketing, and working capital [2] - The total issuance costs (excluding VAT) amounted to 15.99 million yuan, with underwriting fees of 10.75 million yuan [2] Dividend Distribution - According to the announcement for the 2024 annual equity distribution, Shiyijia plans to distribute cash dividends of 10 yuan per 10 shares (including tax) to shareholders, totaling 400.08 million yuan [2] - Additionally, the company will increase its capital by issuing 3 new shares for every 10 shares held, resulting in a total of 120.02 million new shares, raising the total share capital to 520.10 million shares [2]

Investment Rating - The report does not explicitly state an investment rating for the industry or companies involved [5][6]. Core Insights - The 13th Committee's 8th Plenary Session successfully passed the "14th Five-Year Plan" development proposal, emphasizing the transformation direction of "five changes and one advancement" to convert various advantages into development momentum [5][11]. - The focus during the "14th Five-Year" period will be on four major directions to accelerate the construction of a new highland for opening up to the north, including deepening cooperation with Russia and expanding into diverse markets [12]. - The Black龙江板块 index experienced a significant adjustment, dropping 2.63% in November, with a notable decline of 7.31% from November 17 to 21, indicating a bearish market sentiment [21][24]. Summary by Sections Economic Development - The "14th Five-Year" plan outlines 15 parts and 62 articles, detailing development tasks across three major sectors, aiming for a modernized strong province [5][11]. - The province aims to enhance its international economic cooperation and optimize the foreign investment environment, promoting the "Investment Longjiang" brand [12]. Market Performance - The Black龙江板块 index has shown a downward trend, with only five companies achieving positive returns during the period from November 10 to 21, with People's Tongtai leading at a 37.59% increase [21][25]. - The overall performance of the listed companies was weak, with 23 companies experiencing declines of over 5%, and 8 companies seeing declines exceeding 10% [21][25]. Industry Insights - The report highlights the importance of collaboration with companies like UBTECH to enhance talent cultivation and industrial upgrading in the province, focusing on the application of humanoid robots in education [15]. - The province's economic data for the first three quarters of the year indicates a stable growth trend, supported by strong import and export performance [21].

Group 1 - The medical sector showed signs of recovery, with major player United Imaging Healthcare rising over 3%, while other stocks like WuXi AppTec and Aier Eye Hospital fell more than 1% [1] - The largest medical ETF in A-shares (512170) experienced a decline of over 2.8% in the morning but recovered slightly in the afternoon, ultimately dropping over 1%, marking a four-month low [1] - A-shares' three major indices collectively fell over 2% [1] Group 2 - The medical ETF (512170) fell below its six-month moving average and approached a critical yearly support level, with significant trading volume of over 874 million yuan, setting a new monthly high for daily trading [3] - In the first four trading days of the week, over 627 million yuan flowed into the ETF, indicating potential bottom-fishing activity despite the risk of larger sell-offs [3] - The medical ETF has a current scale exceeding 25.3 billion yuan, making it the largest medical-related ETF in the market, with a focus on "medical devices + medical services" [3][4] Group 3 - The ETF's composition includes a significant weighting of over 26% in CXO, along with leading companies in aesthetic medicine, private hospitals, and medical information technology [3] - The ETF is passively tracking the CSI Medical Index, which was established on December 31, 2004, and published on October 31, 2014 [4]

Core Viewpoint - The company Fulejia experienced a decline in stock price and trading volume, with significant changes in financing and shareholding structure, indicating potential challenges in revenue and profit generation [1][2][3]. Financing and Trading Activity - On November 20, Fulejia's stock dropped by 4.58%, with a trading volume of 234 million yuan. The financing buy-in amounted to 28.92 million yuan, while financing repayment was 26.48 million yuan, resulting in a net financing buy of 2.44 million yuan. The total financing and margin balance reached 116 million yuan [1]. - The current financing balance of 115 million yuan represents 5.34% of the circulating market value, which is below the 30th percentile level over the past year, indicating a low financing level [1]. - In terms of margin trading, Fulejia repaid 100 shares and sold 500 shares on November 20, with a selling amount of 13,400 yuan. The margin balance stood at 458,600 yuan, exceeding the 80th percentile level over the past year, indicating a high margin level [1]. Company Performance - For the period from January to September 2025, Fulejia reported a revenue of 1.297 billion yuan, a year-on-year decrease of 11.54%. The net profit attributable to shareholders was 325 million yuan, down 36.73% year-on-year [2]. - Since its A-share listing, Fulejia has distributed a total of 1 billion yuan in dividends [3]. Shareholding Structure - As of November 10, Fulejia had 14,900 shareholders, an increase of 0.69% from the previous period. The average number of circulating shares per shareholder decreased by 0.68% to 5,192 shares [2]. - Among the top ten circulating shareholders, notable changes include a decrease in holdings by major ETFs, with Huabao Zhongzheng Medical ETF reducing its stake by 317,500 shares, and new entry by Hong Kong Central Clearing Limited holding 462,800 shares [3].